PortfoliosLab logoPortfoliosLab logo
BDTX vs. STTK
Performance
Return for Risk
Dividends
Drawdowns
Volatility
Financials

Performance

BDTX vs. STTK - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Black Diamond Therapeutics, Inc. (BDTX) and Shattuck Labs, Inc. (STTK). The values are adjusted to include any dividend payments, if applicable.

Loading graphics...

BDTX vs. STTK - Yearly Performance Comparison


2026 (YTD)202520242023202220212020
BDTX
Black Diamond Therapeutics, Inc.
-12.35%13.55%-23.84%56.11%-66.23%-83.37%-5.12%
STTK
Shattuck Labs, Inc.
76.16%201.65%-83.03%210.00%-72.97%-83.76%170.85%

Fundamentals

EPS

BDTX:

$0.38

STTK:

-$0.89

PS Ratio

BDTX:

1.73

STTK:

396.05

Total Revenue (TTM)

BDTX:

$70.00M

STTK:

$1.00M

Gross Profit (TTM)

BDTX:

$69.91M

STTK:

-$865.00K

EBITDA (TTM)

BDTX:

$17.54M

STTK:

-$52.82M

Returns By Period

In the year-to-date period, BDTX achieves a -12.35% return, which is significantly lower than STTK's 76.16% return.


BDTX

1D
4.93%
1M
-13.77%
YTD
-12.35%
6M
-43.80%
1Y
37.42%
3Y*
4.07%
5Y*
-39.12%
10Y*

STTK

1D
7.89%
1M
64.03%
YTD
76.16%
6M
169.04%
1Y
576.77%
3Y*
29.80%
5Y*
-26.31%
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Black Diamond Therapeutics, Inc.

Shattuck Labs, Inc.

Often compared with BDTX:
BDTX vs. SRPTBDTX vs. RGTI
Often compared with STTK:
STTK vs. QBTSSTTK vs. EQ

Return for Risk

BDTX vs. STTK — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

BDTX
BDTX Risk / Return Rank: 5757
Overall Rank
BDTX Sharpe Ratio Rank: 6060
Sharpe Ratio Rank
BDTX Sortino Ratio Rank: 6060
Sortino Ratio Rank
BDTX Omega Ratio Rank: 5858
Omega Ratio Rank
BDTX Calmar Ratio Rank: 5555
Calmar Ratio Rank
BDTX Martin Ratio Rank: 5353
Martin Ratio Rank

STTK
STTK Risk / Return Rank: 9797
Overall Rank
STTK Sharpe Ratio Rank: 9999
Sharpe Ratio Rank
STTK Sortino Ratio Rank: 9797
Sortino Ratio Rank
STTK Omega Ratio Rank: 9595
Omega Ratio Rank
STTK Calmar Ratio Rank: 9999
Calmar Ratio Rank
STTK Martin Ratio Rank: 9797
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

BDTX vs. STTK - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Black Diamond Therapeutics, Inc. (BDTX) and Shattuck Labs, Inc. (STTK). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


BDTXSTTKDifference

Sharpe ratio

Return per unit of total volatility

0.50

4.26

-3.76

Sortino ratio

Return per unit of downside risk

1.15

4.06

-2.91

Omega ratio

Gain probability vs. loss probability

1.15

1.52

-0.37

Calmar ratio

Return relative to maximum drawdown

0.55

11.66

-11.11

Martin ratio

Return relative to average drawdown

1.09

22.71

-21.62

BDTX vs. STTK - Sharpe Ratio Comparison

The current BDTX Sharpe Ratio is 0.50, which is lower than the STTK Sharpe Ratio of 4.26. The chart below compares the historical Sharpe Ratios of BDTX and STTK, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Loading graphics...

Sharpe Ratios by Period


BDTXSTTKDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

0.50

4.26

-3.76

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

-0.30

-0.22

-0.07

Sharpe Ratio (All Time)

Calculated using the full available price history

-0.31

-0.16

-0.15

Correlation

The correlation between BDTX and STTK is 0.25, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


Dividends

BDTX vs. STTK - Dividend Comparison

Neither BDTX nor STTK has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

BDTX vs. STTK - Drawdown Comparison

The maximum BDTX drawdown since its inception was -97.21%, roughly equal to the maximum STTK drawdown of -98.73%. Use the drawdown chart below to compare losses from any high point for BDTX and STTK.


Loading graphics...

Drawdown Indicators


BDTXSTTKDifference

Max Drawdown

Largest peak-to-trough decline

-97.21%

-98.73%

+1.52%

Max Drawdown (1Y)

Largest decline over 1 year

-58.32%

-43.69%

-14.63%

Max Drawdown (5Y)

Largest decline over 5 years

-95.56%

-98.06%

+2.50%

Current Drawdown

Current decline from peak

-95.25%

-88.84%

-6.41%

Average Drawdown

Average peak-to-trough decline

-78.15%

-82.89%

+4.74%

Ulcer Index

Depth and duration of drawdowns from previous peaks

29.69%

22.44%

+7.25%

Volatility

BDTX vs. STTK - Volatility Comparison

Black Diamond Therapeutics, Inc. (BDTX) has a higher volatility of 24.26% compared to Shattuck Labs, Inc. (STTK) at 22.89%. This indicates that BDTX's price experiences larger fluctuations and is considered to be riskier than STTK based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading graphics...

Volatility by Period


BDTXSTTKDifference

Volatility (1M)

Calculated over the trailing 1-month period

24.26%

22.89%

+1.37%

Volatility (6M)

Calculated over the trailing 6-month period

52.93%

56.80%

-3.87%

Volatility (1Y)

Calculated over the trailing 1-year period

75.09%

137.15%

-62.06%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

132.20%

117.53%

+14.67%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

124.03%

115.46%

+8.57%

Financials

BDTX vs. STTK - Financials Comparison

This section allows you to compare key financial metrics between Black Diamond Therapeutics, Inc. and Shattuck Labs, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0020.00M40.00M60.00MAprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025AprilJuly0
1.00M
(BDTX) Total Revenue
(STTK) Total Revenue
Values in USD except per share items